Session 2E: Characterization of Amyloid Beta Oligomers and Co-Localized Proteins in Alzheimer's Disease
Session Number
Session 2E:3rd Presentation
Advisor(s)
William Klein and Kirsten Viola, Northwestern University
Location
Room A113
Start Date
28-4-2017 10:00 AM
End Date
28-4-2017 11:15 AM
Abstract
Animal models are essential to our current understanding of disease progression, pathology and diagnosis. Created as models for pre-clinical studies, animal models have served as excellent indicators of protein regulation, gene expression, and immunology, all of which have provided insight into the growing field of therapeutics and treatments. One particular illnesses of interest, Alzheimer’s disease, is being studied using animal models. AD is characterized by the proteolytic processing of the Amyloid Beta precursor protein which results in soluble forms of Aβ aggregates called Aβ oligomers (known as ADDLs). ADDLs in the brain, considered a propagator of synaptic loss and neurotoxicity, are being investigated using transgenic mice that are genetically engineered with distinct mutations specific to ADDL production and AD. Alternative methods for studying ADDL neurotoxicity have used intracerebroventricular injection of ADDLs. These approaches have provided a greater understanding of ADDLs involvement in AD, but have also shown that other proteins function alongside ADDLs to induce the neuronal dysfunction, memory and learning disabilities associated with Alzheimer's disease. Our study investigates how ADDL pathology develops in unison with other molecules in Tg 5XFAD mice. This understanding will open up the possibilities for new treatment targets and better methods for early identification.
Session 2E: Characterization of Amyloid Beta Oligomers and Co-Localized Proteins in Alzheimer's Disease
Room A113
Animal models are essential to our current understanding of disease progression, pathology and diagnosis. Created as models for pre-clinical studies, animal models have served as excellent indicators of protein regulation, gene expression, and immunology, all of which have provided insight into the growing field of therapeutics and treatments. One particular illnesses of interest, Alzheimer’s disease, is being studied using animal models. AD is characterized by the proteolytic processing of the Amyloid Beta precursor protein which results in soluble forms of Aβ aggregates called Aβ oligomers (known as ADDLs). ADDLs in the brain, considered a propagator of synaptic loss and neurotoxicity, are being investigated using transgenic mice that are genetically engineered with distinct mutations specific to ADDL production and AD. Alternative methods for studying ADDL neurotoxicity have used intracerebroventricular injection of ADDLs. These approaches have provided a greater understanding of ADDLs involvement in AD, but have also shown that other proteins function alongside ADDLs to induce the neuronal dysfunction, memory and learning disabilities associated with Alzheimer's disease. Our study investigates how ADDL pathology develops in unison with other molecules in Tg 5XFAD mice. This understanding will open up the possibilities for new treatment targets and better methods for early identification.